USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
The Wonderful Accident Behind a Christmas Classic
Actors Recorded Videos for ‘Vladimir.’ It Turned Into Russian Propaganda.
The Mysterious CEO Leading Shein to an IPO
Janet Yellen on Inflation and the U.S. Economy
Big Donors Clash with Universities Over Antisemitism, Free Speech
Artificial: Episode 2, Selling Out
Does Nikki Haley Have a Chance At Beating Trump?
Meta Is Struggling to Boot Pedophiles Off Facebook and Instagram
Why Goldman Sachs and Apple Weren't Happily Ever After
Why Some Opioid Victims Are Challenging Purdue’s Settlement
She Tried to Get Sober. She Got Scammed Instead.
Artificial: Episode 1, The Dream
Charlie Munger: Curmudgeon, Sage and Investing Legend
The Oil Giant Hosting This Year’s U.N. Climate Summit
Lewd Photos, Booze and Bullying: Inside the FDIC’s Toxic Culture
Introducing - Artificial: The OpenAI Story
The Family Drama Inside Estée Lauder
The Fall of (Another) Crypto King
Pig-Butchering: A Texting Scam With a Crypto Twist
Canned or Homemade? America’s Biggest Cranberry Company Wins Either Way
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Minute Briefing
WSJ Tech News Briefing
Marketplace Tech